

*For more information, contact:*  
The PATH Malaria Vaccine Initiative  
Preeti Singh at +1 301 280 5722 or [psingh@burnesscommunications.com](mailto:psingh@burnesscommunications.com)

Johns Hopkins Bloomberg School of Public Health  
Timothy Parsons at +1 410 955 7619 or [tmparson@jhsph.edu](mailto:tmparson@jhsph.edu)

Sabin Vaccine Institute  
Eteena Tadjioqueu at +1 202 265 6517 or [eteena.tadjioqueu@sabin.org](mailto:eteena.tadjioqueu@sabin.org)

## **First steps taken toward the development of a malaria transmission-blocking vaccine**

### **PATH Malaria Vaccine Initiative announces collaboration with Johns Hopkins Bloomberg School of Public Health and Sabin Vaccine Institute**

**BETHESDA, MD, January 15, 2010** — The PATH Malaria Vaccine Initiative (MVI) today announced a new collaboration to initiate development toward a vaccine that may eventually help eliminate and eradicate malaria. This collaboration with the Johns Hopkins Bloomberg School of Public Health (JHSPH) and the Sabin Vaccine Institute (Sabin) marks MVI's first investment in transmission-blocking vaccines (TBVs). This vaccine approach aims to stop the malaria parasite from developing in the mosquito, effectively blocking transmission of malaria from mosquitoes to humans. Malaria kills nearly 900,000 people per year, most of them children younger than age five.

“The heart-breaking devastation caused by malaria cannot be overstated,” according to Dr. Peter Agre, Nobel Laureate and Director of the Johns Hopkins Malaria Research Institute (JHMRI). “Blocking transmission by novel vaccines may provide the approach needed to stop the epidemic. MVI deserves great credit for supporting potentially exciting research that would otherwise be abandoned due to lack of precedent.”

“Although eradication is a very long-term and aspirational goal, we are excited by the potential of transmission-blocking vaccines to significantly limit the spread of malaria infection,” noted Dr. Christian Loucq, Director of MVI. “In combination with other interventions, we believe a successful TBV would provide another important tool in the fight against malaria.”

Over the next 18 months, MVI's partners will collaborate to produce and characterize an antigen that can activate the body's defenses to disrupt the complex human-mosquito transmission cycle of malaria. An antigen is any substance that triggers the immune system to produce antibodies against it.

The development team will identify the optimal conditions needed to manufacture clinical supplies of AnAPN1, a mosquito antigen that appears to play a major role in parasite establishment within the mosquito. Preliminary field research has shown that antibodies induced by this antigen are capable of blocking transmission of the two deadliest malaria parasites, *Plasmodium falciparum* and *P. vivax*. When a mosquito takes blood from a vaccinated person, these antibodies prevent the parasite from attaching to and invading the mosquito's gut.

“The antibodies that we have produced are effective against multiple malaria parasites and, therefore, this antigen may constitute the basis for a future ‘universal’ or pan-malaria transmission-blocking vaccine.” said Dr. Rhoel Dinglasan, lead researcher on this project and faculty member at JHSPH. “This could have a tremendous impact on malaria transmission, even extending beyond those individuals we can reach through a vaccination campaign.”

“We look forward to supporting MVI’s innovative efforts in the development of transmission-blocking vaccines for malaria,” said Dr. Ami Shah Brown, Director of Vaccine Operations for the Sabin Vaccine Institute. “Together with our partners at The George Washington University, we are very excited to utilize our existing vaccine development capabilities and work with MVI and JHSPH to develop the AnAPN1 antigen.”

This collaboration—MVI’s first project focused on TBVs—reflects MVI’s redesigned research and development strategy. The new strategy encompasses a broader outlook on malaria vaccine development and promotes early investment in a variety of approaches that have the potential to reach the malaria community’s long-term goal of a vaccine that is at least 80 percent effective against clinical disease for more than four years by 2025. Further, MVI is increasing support for vaccines targeting clinical disease caused by *P. vivax*, as well as vaccines that could interrupt the cycle of transmission of malaria parasites; two aspects of malaria vaccine development that have historically been poorly funded. These efforts are spurred by a renewed long-term commitment within the malaria community to eradicate the disease.

###

#### **About the PATH Malaria Vaccine Initiative (MVI)**

MVI is a global program established at PATH through an initial grant from the Bill & Melinda Gates Foundation. MVI’s mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world. MVI’s vision is a world free from malaria. For more information, visit [www.malariavaccine.org](http://www.malariavaccine.org).

#### **About PATH**

PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH’s work improves global health and well-being. For more information, visit [www.path.org](http://www.path.org).

#### **About the Johns Hopkins Bloomberg School of Public Health**

As a leading international authority on public health, the Johns Hopkins Bloomberg School of Public Health is dedicated to protecting health and saving lives. Every day, the School works to keep millions safe from illness and injury by pioneering new research, deploying its knowledge and expertise in the field, and educating tomorrow’s scientists and practitioners in the global defense of human life. For more information, visit: [www.jhsph.edu](http://www.jhsph.edu).

#### **About the Sabin Vaccine Institute**

Sabin Vaccine Institute is a nonprofit organization dedicated to reducing human suffering from infectious and neglected diseases. Through its efforts in vaccine research, development, and advocacy, Sabin works to provide greater access to vaccines and essential medicines for millions stuck in pain, poverty, and despair. Founded in 1993 in honor of Dr. Albert B. Sabin, discoverer of the oral polio vaccine, the Sabin Vaccine Institute works with prestigious institutions, scientists, medical professionals, and organizations to provide short- and long-term solutions that result in healthier individuals, families, and communities around the globe. For more information about Sabin’s research and commitment, visit: [www.sabin.org](http://www.sabin.org).